Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China

INTRODUCTION: A phase 3 (RA-BEAM study) clinical trial reported that baricitinib (BCT) + methotrexate (MTX) had clinical improvement compared with adalimumab (ADA) + MTX as a first-line strategy in patients with rheumatoid arthritis (RA) who had inadequate responses to MTX monotherapy. However, from...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217482/
https://www.ncbi.nlm.nih.gov/pubmed/33893943
http://dx.doi.org/10.1007/s40744-021-00308-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217482/
https://www.ncbi.nlm.nih.gov/pubmed/33893943
http://dx.doi.org/10.1007/s40744-021-00308-w

Ejemplares similares